Last $102.62 USD
Change Today +0.53 / 0.52%
Volume 3.7M
JNJ On Other Exchanges
Symbol
Exchange
New York
Xetra
Mexico
Sao Paulo
Bogota
As of 12:59 PM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

johnson & johnson (JNJ) Key Developments

Johnson & Johnson expected to report Fiscal Year 2014 results on January 28, 2015. This event was calculated by Capital IQ (Created on January 22, 2015).

Johnson & Johnson expected to report Fiscal Year 2014 results on January 28, 2015. This event was calculated by Capital IQ (Created on January 22, 2015).

Johnson & Johnson Provides Earnings Guidance for the Full Year 2015

Johnson & Johnson provided earnings guidance for the full year 2015. The company forecast full-year 2015 earnings ranging from $6.12 to $6.27 per share - well above the $5.52 in adjusted earnings per share it generated for all of 2014.

Johnson & Johnson Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 28, 2014

Johnson & Johnson reported unaudited consolidated earnings results for the fourth quarter and full year ended December 28, 2014. For the quarter, sales to customers were $18,254 million against $18,355 million a year ago. Earnings before provision for taxes on income were $2,703 million against $2,750 million a year ago. Net earnings were $2,521 million against $3,519 million a year ago. Diluted net earnings per share were $0.89 against $1.23 a year ago. Adjusted earnings before provision for taxes and net earnings before provision for taxes on income was $3,925 million against $3,909 million a year ago. Diluted net earnings per share were $1.27 against $1.24 a year ago. For the full year, sales to customers were $74,331 million against $71,312 million a year ago. Earnings before provision for taxes on income were $20,563 million against $15,471 million a year ago. Net earnings were $16,323 million against $13,831 million a year ago. Diluted net earnings per share were $5.70 million against $4.81 million a year ago. Adjusted earnings before provision for taxes and net earnings before provision for taxes on income was $21,195 million against $19,169 million a year ago. Net earnings were $17,105 million against $15,876 million a year ago. Diluted net earnings per share were $5.97 against $5.52 million a year ago.

Depomed Inc. to Buy Pain Drug from Johnson and Johnson for $1.05 Billion

Depomed Inc. will buy a pain drug from Johnson and Johnson for $1.05 billion, adding a product to its pain and neurology portfolio. Depomed will take the rights to tapentadol hydrochloride (Nucynta), an opioid pain pill that sold $166 million in the 1-year period that ended in September. Depomed said it plans to reintroduce the drug and promote it for both chronic pain and nerve damage caused by diabetes. The medicine has patent protection until 2022.

Johnson & Johnson Announces Cash Dividend for First Quarter of 2015 Payable on March 10, 2015

Johnson & Johnson announced that its Board of Directors has declared a cash dividend for the first quarter of 2015 of $0.70 per share on the company's common stock. The dividend is payable on March 10, 2015 to shareholders of record at the close of business on February 24, 2015. The ex-dividend date is February 20, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JNJ:US $102.62 USD +0.53

JNJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $24.12 USD -0.259
Intel Corp $34.26 USD +0.075
Merck & Co Inc $62.23 USD -0.33
Pfizer Inc $32.32 USD -0.28
Procter & Gamble Co/The $86.03 USD -0.46
View Industry Companies
 

Industry Analysis

JNJ

Industry Average

Valuation JNJ Industry Range
Price/Earnings 17.9x
Price/Sales 3.9x
Price/Book 3.7x
Price/Cash Flow 17.5x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JOHNSON & JOHNSON, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.